KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Non-Current Liabilities (2023 - 2025)

Recursion Pharmaceuticals' Total Non-Current Liabilities history spans 3 years, with the latest figure at $341.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 16.6% year-over-year to $341.2 million; the TTM value through Dec 2025 reached $341.2 million, down 16.6%, while the annual FY2025 figure was $341.2 million, 16.6% down from the prior year.
  • Total Non-Current Liabilities reached $341.2 million in Q4 2025 per RXRX's latest filing, down from $351.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $409.1 million in Q4 2024 to a low of $188.4 million in Q2 2024.
  • Average Total Non-Current Liabilities over 3 years is $303.4 million, with a median of $346.4 million recorded in 2025.
  • Peak YoY movement for Total Non-Current Liabilities: soared 115.01% in 2024, then decreased 16.6% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $190.3 million in 2023, then skyrocketed by 115.01% to $409.1 million in 2024, then fell by 16.6% to $341.2 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Total Non-Current Liabilities are $341.2 million (Q4 2025), $351.5 million (Q3 2025), and $381.6 million (Q2 2025).